脂肪性肝病与慢性肾脏病相互作用机制及研究进展

doi:10.3969/j.issn.1004-583X.2025.12.014

摘要/Abstract

摘要：

代谢相关脂肪性肝病原名非酒精性脂肪性肝病，是发达国家慢性肝病最常见的病因，在发展中国家的发病率不断增加。慢性肾脏病（chronic kidney disease，CKD）是威胁人类健康的常见慢性疾病之一，而代谢功能紊乱（高血压和糖尿病等）正成为CKD的主要病因。炎症因子、氧化应激、胰岛素抵抗、肠道微生物群失调等均与脂肪性肝病和 CKD 的相互作用有关。本研究对脂肪性肝病与 CKD相互作用机制及研究进展进行综述，旨在为临床治疗提供理论依据。

关键词: 脂肪性肝病, 慢性肾脏病, 病理机制, 机器学习模型

中图分类号:

R575.5
R692

曲益辉, 罗群, 蔡珂丹. 脂肪性肝病与慢性肾脏病相互作用机制及研究进展[J]. 临床荟萃, 2025, 40(12): 1130-1135.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2025.12.014

https://www.lchc.cn/CN/Y2025/V40/I12/1130

参考文献 60

[1]	Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77(5): 1797-1835.doi:10.1097/hep.0000000000000323. pmid: 36727674
[2]	中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 中华肝脏病杂志, 2024, 32(5): 418-434.doi:10.3760/cma.j.cn501113-20240327-00163.
[3]	Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209.doi:10.1016/j.jhep.2020.03.039. pmid: 32278004
[4]	Mantovani A, Zusi C, Dalbeni A, et al. Risk of kidney dysfunction in NAFLD[J]. Curr Pharm Des, 2020, 26(10): 1045-1061.doi:10.2174/1381612825666191026113119.
[5]	Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease[J]. J Hepatol, 2020, 72(4): 785-801.doi:10.1016/j.jhep.2020.01.013. pmid: 32059982
[6]	Cheung A, Ahmed A. Nonalcoholic fatty liver disease and chronic kidney disease: A review of links and risks[J]. Clin Exp Gastroenterol, 2021, 14: 457-465.doi:10.2147/ceg.S226130. pmid: 34819740
[7]	Tao Z, Li Y, Cheng B, et al. Influence of nonalcoholic fatty liver disease on the occurrence and severity of chronic kidney disease[J]. J Clin Transl Hepatol, 2022, 10(1): 164-173.doi:10.14218/jcth.2021.00171. pmid: 35233386
[8]	Wang TY, Wang RF, Bu ZY, et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease[J]. Nat Rev Nephrol, 2022, 18(4): 259-268.doi:10.1038/s41581-021-00519-y.
[9]	Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: An updated meta-analysis[J]. Gut, 2022, 71(1): 156-162.doi:10.1136/gutjnl-2020-323082. pmid: 33303564
[10]	Targher G, Bertolini L, Rodella S, et al. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis[J]. Clin J Am Soc Nephrol, 2010, 5(12): 2166-2171.doi:10.2215/cjn.05050610.
[11]	Musso G, Gambino R, Tabibian JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-analysis[J]. PLoS Med, 2014, 11(7): e1001680.doi:10.1371/journal.pmed.1001680.
[12]	Gofton C, Upendran Y, Zheng MH, et al. MAFLD: How is it different from NAFLD?[J]. Clin Mol Hepatol, 2023, 29(Suppl): S17-S31.doi:10.3350/cmh.2022.0367.
[13]	Yamamura S, Eslam M, Kawaguchi T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD[J]. Liver Int, 2020, 40(12): 3018-3030.doi:10.1111/liv.14675.
[14]	Su W, Chen M, Xiao L, et al. Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease[J]. Front Public Health, 2022, 10: 1047794.doi:10.3389/fpubh.2022.1047794.
[15]	Liang Y, Chen H, Liu Y, et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: A 4.6-year cohort study in China[J]. J Clin Endocrinol Metab, 2022, 107(1): 88-97.doi:10.1210/clinem/dgab641.
[16]	Kwon SY, Park J, Park SH, et al. MAFLD and NAFLD in the prediction of incident chronic kidney disease[J]. Sci Rep, 2023, 13(1): 1796.doi:10.1038/s41598-023-27762-6. pmid: 36720976
[17]	孙铭辰, 赵翠荣, 卢翠翠, 等. 线粒体功能障碍在糖尿病肾病足细胞脂代谢中作用的研究现状[J]. 中国临床药理学杂志, 2024, 40(17): 2601-2605.doi:10.13699/j.cnki.1001-6821.2024.17.030.
[18]	Duan Y, Luo J, Pan X, et al. Association between inflammatory markers and non-alcoholic fatty liver disease in obese children[J]. Front Public Health, 2022, 10: 991393.doi:10.3389/fpubh.2022.991393.
[19]	Cai X, Sun L, Liu X, et al. Non-alcoholic fatty liver disease is associated with increased risk of chronic kidney disease[J]. Ther Adv Chronic Dis, 2021, 12: 20406223211024361.doi:10.1177/20406223211024361.
[20]	Cao N, Liu X, Deng Y, et al. Reactive oxygen species/c-Jun N-terminal kinase/nuclear factor kappa-B signaling molecules are involved in pe-riodontitis-induced liver injury by regulating apoptosis[J]. Hua Xi Kou Qiang Yi Xue Za Zhi, 2022, 40(5): 532-540.doi:10.7518/hxkq.2022.05.005.
[21]	Kishi S, Nagasu H, Kidokoro K, et al. Oxidative stress and the role of redox signalling in chronic kidney disease[J]. Nat Rev Nephrol, 2024, 20(2): 101-119.doi:10.1038/s41581-023-00775-0.
[22]	Wang S, Jia Q, Liu X, et al. Hyperoside modulates bile acid and fatty acid metabolism, presenting a potentially promising treatment for non-alcoholic fatty liver disease[J]. J Adv Res, 2025.doi:10.1016/j.jare.2025.05.014.
[23]	Peiseler M, Schwabe R, Hampe J, et al. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease-novel insights into cellular communication circuits[J]. J Hepatol, 2022, 77(4): 1136-1160.doi:10.1016/j.jhep.2022.06.012. pmid: 35750137
[24]	Niu B, Liu J, Zhou H, et al. ACT001 alleviates MASLD through gut microbiota-bile acid-FXR axis in mice[J]. Ann Med, 2025, 57(1): 2580773.doi:10.1080/07853890.2025.2580773.
[25]	Sun DQ, Yuan F, Fu MZ, et al. Farnesoid X receptor activation protects against renal fibrosis via modulation of β-catenin signaling[J]. Mol Metab, 2024, 79: 101841.doi:10.1016/j.molmet.2023.101841.
[26]	Mitrofanova A, Merscher S, Fornoni A. Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease[J]. Nat Rev Nephrol, 2023, 19(10): 629-645.doi:10.1038/s41581-023-00741-w. pmid: 37500941
[27]	Smith GI, Shankaran M, Yoshino M, et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease[J]. J Clin Invest, 2020, 130(3): 1453-1460.doi:10.1172/jci134165. pmid: 31805015
[28]	Kuchay MS, Choudhary NS, Mishra SK. Pathophysiological mechanisms underlying MAFLD[J]. Diabetes Metab Syndr, 2020, 14(6): 1875-1887.doi:10.1016/j.dsx.2020.09.026. pmid: 32998095
[29]	Li M, Chi X, Wang Y, et al. Trends in insulin resistance:Insights into mechanisms and therapeutic strategy[J]. Signal Transduct Target Ther, 2022, 7(1): 216.doi:10.1038/s41392-022-01073-0.
[30]	Zhou B, Luo Y, Bi H, et al. Amelioration of nonalcoholic fatty liver disease by inhibiting the deubiquitylating enzyme RPN11[J]. Cell Metab, 2024, 36(10): 2228-2244.e2227.doi:10.1016/j.cmet.2024.07.014. pmid: 39146936
[31]	Parwani K, Mandal P. Role of advanced glycation end products and insulin resistance in diabetic nephropathy[J]. Arch Physiol Biochem, 2023, 129(1): 95-107.doi:10.1080/13813455.2020.1797106.
[32]	Sebastian SA, Padda I, Johal G. Cardiovascular-kidney-metabolic (CKM) syndrome: A state-of-the-art review[J]. Curr Probl Cardiol, 2024, 49(2): 102344.doi:10.1016/j.cpcardiol.2023.102344.
[33]	Ma J, Staler DW, Mahato RI. Targeting cAMP signaling and phosphodiesterase 4 for liver disease treatment[J]. Med Chem Res, 2024, 33(8): 1339-1353.doi:10.1007/s00044-024-03267-3. pmid: 40801006
[34]	Xiao Y, Wang J, Zhang H, et al. Linarin alleviates high-fat diet-induced hepatic steatosis by inhibiting PDE4D and activating the cAMP/PKA/CREB pathway[J]. Free Radic Biol Med, 2025, 239: 116-129.doi:10.1016/j.freeradbiomed.2025.07.030.
[35]	Tao X, He H, Peng J, et al. Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: Therapeutic role of roflumilast[J]. Pharmacol Res, 2022, 175: 106004.doi:10.1016/j.phrs.2021.106004.
[36]	Lian CY, Zhai ZZ, Li ZF, et al. High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms[J]. Chem Biol Interact, 2020, 330: 109199.doi:10.1016/j.cbi.2020.109199.
[37]	Tao X, Chen C, Huang Z, et al. Genetic deletion of phosphodiesterase 4D in the liver improves kidney damage in high-fat fed mice: Liver-kidney crosstalk[J]. Cell Death Dis, 2023, 14(4): 273.doi:10.1038/s41419-023-05792-2. pmid: 37072403
[38]	Alisi A, McCaughan G, Grønbæk H. Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: Clinical impact[J]. Hepatol Int, 2024, 18(Suppl 2): 861-872.doi:10.1007/s12072-024-10674-6.
[39]	Giordano L, Ahmed S, van der Made TK, et al. Gut microbial-derived short chain fatty acids enhance kidney proximal tubule cell secretory function[J]. Biomed Pharmacother, 2025, 188: 118214.doi:10.1016/j.biopha.2025.118214.
[40]	Lei Y, Xiong G, Lei D, et al. Gut microbiota-derived TMAO drives the kidney-bone-vascular axis in chronic kidney disease complications[J]. Ren Fail, 2025, 47(1): 2575434.doi:10.1080/0886022x.2025.2575434.
[41]	He M, Wei W, Zhang Y, et al. Gut microbial metabolites SCFAs and chronic kidney disease[J]. J Transl Med, 2024, 22(1): 172.doi:10.1186/s12967-024-04974-6. pmid: 38369469
[42]	Miao C, Wang L, Wang H, et al. Lacticaseibacillus plantarum postbiotics prepared by the combined technique of pasteurization and ultrasound: Effective measures to alleviate obesity based on the SCFAs-GPR41/GPR43 signaling pathway[J]. Food Funct, 2024, 15(22): 11005-11019.doi:10.1039/d4fo03591g.
[43]	Carmody RN, Bisanz JE. Roles of the gut microbiome in weight management[J]. Nat Rev Microbiol, 2023, 21(8): 535-550.doi:10.1038/s41579-023-00888-0. pmid: 37138047
[44]	Sun DQ, Zheng KI, Xu G, et al. PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels[J]. Liver Int, 2020, 40(1): 107-119.doi:10.1111/liv.14251.
[45]	Mantovani A, Taliento A, Zusi C, et al. PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings[J]. Liver Int, 2020, 40(5): 1130-1141.doi:10.1111/liv.14419. pmid: 32125756
[46]	Akuta N, Kawamura Y, Arase Y, et al. PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD[J]. BMC Gastroenterol, 2021, 21(1): 434.doi:10.1186/s12876-021-02020-z. pmid: 34798835
[47]	Mantovani A, Pelusi S, Margarita S, et al. Adverse effect of PNPLA3 p.I148M genetic variant on kidney function in middle-aged individuals with metabolic dysfunction[J]. Aliment Pharmacol Ther, 2023, 57(10): 1093-1102.doi:10.1111/apt.17477.
[48]	Mantovani A, Targher G. PNPLA3 variation and kidney disease[J]. Liver Int, 2025, 45(3): e16010. doi:10.1111/liv.16010.
[49]	Cherubini A, Casirati E, Tomasi M, et al. PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date[J]. Expert Opin Ther Targets, 2021, 25(12): 1033-1043.doi:10.1080/14728222.2021.2018418.
[50]	Donati B, Motta BM, Pingitore P, et al. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage[J]. Hepatology, 2016, 63(3): 787-798.doi:10.1002/hep.28370. pmid: 26605757
[51]	Meroni M, Longo M, Tria G, et al. Genetics is of the essence to face NAFLD[J]. Biomedicines, 2021, 9(10): 1359. doi:10.3390/biomedicines9101359.
[52]	Park J, Zhao Y, Zhang F, et al. IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease[J]. J Hepatol, 2023, 78(1): 45-56.doi:10.1016/j.jhep.2022.08.022.
[53]	Chen S, Chen T, Xu C, et al. Iron overload exaggerates renal ischemia-reperfusion injury by promoting tubular cuproptosis via interrupting function of LIAS[J]. Redox Biol, 2025, 86: 103795.doi:10.1016/j.redox.2025.103795.
[54]	Shin JA, Hwang Y, Park H, et al. Renoprotective effects of MIT-001 in ischemia-reperfusion injury: Modulation of ferroptosis, ROS and fibrotic markers[J]. J Cell Mol Med, 2025, 29(20): e70914.doi:10.1111/jcmm.70914.
[55]	Tao L, Yang X, Ge C, et al. Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH[J]. Cell Metab, 2024, 36(10): 2190-2206.e2195.doi:10.1016/j.cmet.2024.07.013. pmid: 39142286
[56]	Zhang J, Wang Y, Fan M, et al. Reactive oxygen species regulation by NCF1 governs ferroptosis susceptibility of Kupffer cells to MASH[J]. Cell Metab, 2024, 36(8): 1745-1763.e1746.doi:10.1016/j.cmet.2024.05.008.
[57]	Corradini E, Buzzetti E, Dongiovanni P, et al. Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD[J]. J Hepatol, 2021, 75(3): 506-513.doi:10.1016/j.jhep.2021.03.014. pmid: 33774058
[58]	Chen IC, Chou LJ, Huang SC, et al. Machine learning-based comparison of factors influencing estimated glomerular filtration rate in Chinese women with or without non-alcoholic fatty liver[J]. World J Clin Cases, 2024, 12(15): 2506-2521.doi:10.12998/wjcc.v12.i15.2506. pmid: 38817230
[59]	Cao Y, Du Y, Jia W, et al. Identification of biomarkers for the diagnosis of chronic kidney disease (CKD) with non-alcoholic fatty liver disease (NAFLD) by bioinformatics analysis and machine learning[J]. Front Endocrinol (Lausanne), 2023, 14: 1125829.doi:10.3389/fendo.2023.1125829.
[60]	Fan J, Li N, Lu Y, et al. Identification of key genes in membranous nephropathy and non-alcoholic fatty liver disease by bioinformatics and machine learning[J]. Front Immunol, 2025, 16: 1564288.doi:10.3389/fimmu.2025.1564288.

脂肪性肝病与慢性肾脏病相互作用机制及研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 60

相关文章 15

编辑推荐

Metrics

本文评价

[1]	肇雪婷, 白佳雯, 孙军. 代谢相关脂肪性肝病肝纤维化危险因素分析及构建预测模型[J]. 临床荟萃, 2025, 40(5): 417-422.
[2]	张宏涛, 钟美娇, 高敬洋, 李士杰, 于娜新, 范鑫, 陈立宁, 张扬, 王志奎, 边爱淑. HEP/SF比值对维持性腹膜透析患者贫血的评估价值[J]. 临床荟萃, 2025, 40(5): 434-438.
[3]	童明霞, 陈柯, 向小聪, 周丽峰. 中青年体检人群瘦型代谢相关脂肪性肝病及其危险因素分析[J]. 临床荟萃, 2025, 40(2): 128-132.
[4]	史双伟, 饶小娟, 解丽然, 方一凡, 王姗姗. 甲状腺功能正常的2型糖尿病患者甲状腺激素敏感性与非酒精性脂肪肝的相关性[J]. 临床荟萃, 2025, 40(2): 133-137.
[5]	苟彩霞, 张洁, 包依夏姆·阿巴拜克力, 王一鸣, 姚磊, 郑嵘炅, 潘金良, 鲁晓擘. 体检人群睡眠质量与代谢相关脂肪性肝病的影响因素分析[J]. 临床荟萃, 2025, 40(1): 33-38.
[6]	马苗苗, 王义艳, 温甜甜, 马丽群. 甘油三酯-葡萄糖指数与阻塞性睡眠呼吸暂停综合征相关性的研究进展[J]. 临床荟萃, 2024, 39(9): 851-854.
[7]	熊璐, 郭莲. 2型糖尿病患者25(OH)D和SUA/SCr与合并非酒精性脂肪肝的相关性[J]. 临床荟萃, 2024, 39(8): 706-711.
[8]	王琦, 陈宏. 维生素D在支气管哮喘和慢性阻塞性肺疾病治疗中的应用进展[J]. 临床荟萃, 2024, 39(1): 88-91.
[9]	杨星梦, 马晓迎, 生玉平, 刘烨, 张浩然, 徐海平, 王娜, 孙福云. 慢性肾脏病5期非透析患者同型半胱氨酸与腹主动脉钙化的相关性[J]. 临床荟萃, 2024, 39(1): 30-33.
[10]	杨小雄, 杨帆, 魏小果. 肠-微生物群-肝轴与代谢相关脂肪性肝病的研究进展[J]. 临床荟萃, 2023, 38(6): 559-563.
[11]	宗廷妮, 戴光荣, 赵晓宇, 李瑞风, 柴聪敏. 代谢相关脂肪性肝病靶向药物治疗进展[J]. 临床荟萃, 2023, 38(4): 373-376.
[12]	曹宇萌, 张海燕, 刘立新. 非酒精性脂肪性肝病的病理改变与血清铁蛋白和血清铁含量变化关系的meta分析[J]. 临床荟萃, 2023, 38(3): 197-207.
[13]	刘亚鑫, 郭岚, 王泽凯, 牛凯. 慢性肾脏病合并骨质疏松症治疗的研究进展[J]. 临床荟萃, 2023, 38(12): 1146-1149.
[14]	熊璐, 郭莲. 胰岛素样生长因子-1及其结合蛋白与非酒精性脂肪性肝病发生发展的研究进展[J]. 临床荟萃, 2023, 38(10): 935-939.
[15]	王馨雪, 赵丹, 柳惠未, 叶桦, 徐梦丹. 先天免疫反应与非酒精性脂肪性肝病关系的研究进展[J]. 临床荟萃, 2022, 37(9): 846-854.